Industry & Policy News

[RedMedNet] The month’s top grants in regenerative medicine, sourced from Dimensions, include projects on: high-resolution lineage tracing of developmental hematopoiesis, ROS signaling in wound healing versus tissue repair, and microglia engineering and replacement to treat brain disease.

[Oxurion] Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase II, Part B clinical trial for diabetic macular edema. Oxurion’s investigators have successfully over-enrolled the trial with a total of 112 patients.

[Bristol Myers Squibb] Bristol Myers Squibb announced that the US FDA has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens, Massachusetts.

[University of Birmingham] Adults and children with cancer will continue to benefit from world-class clinical trials led by the University of Birmingham thanks to a new £10 million grant from Cancer Research UK.

[Eureka Therapeutics, Inc.] Eureka Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer, including hepatoblastoma, hepatocellular neoplasm not otherwise specified, and hepatocellular carcinoma.

[Quell Therapeutics Ltd.] Under the terms of the agreement, Quell’s proprietary toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be leveraged to develop autologous multi-modular Treg cell therapy candidates for Type 1 Diabetes and Inflammatory Bowel Disease.